Moderna is trading at $151.09 (-4.87%) as investors continue taking profits after its extraordinary recent rally tied to positive Phase 3 cancer-vaccine results.
- Similar post-rally declines were explicitly attributed to profit-taking and valuation concerns, without a new negative company catalyst.
- The August 25 Wolfe Research upgrade and renewed optimism helped Moderna close 14.36% higher at $158.83, but today’s decline appears to reflect continued volatility and gain-locking rather than worsening clinical news.